Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense oligonucleotides as therapeutic agents

A Alama1, F Barbieri, M Cagnoli

  • 1Department of Preclinical Oncology, Laboratory of Pharmacology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italia.

Pharmacological Research
|February 7, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Collaborative neurocardiology board meetings for decision-making in stroke care: a real-world experience.

Neurological research and practice·2026
Same author

Collaborative neurocardiology board meetings for decision-making in stroke care: a real-world experience.

Neurological research and practice·2026
Same author

Affine diffractive beam dividers.

Journal of the Optical Society of America. A, Optics, image science, and vision·2024
Same author

Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078].

ESMO open·2021
Same author

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.

ESMO open·2021
Same author

Is dental general anaesthesia in children an outdated concept? A retrospective analysis.

European journal of paediatric dentistry·2020

Antisense oligonucleotides offer a promising approach to gene expression modulation. This technology is explored for therapeutic applications in cancer, viral infections, and genetic disorders.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry

Background:

  • Antisense oligonucleotides (ASOs) are short nucleic acid sequences designed to bind to specific RNA targets.
  • This binding forms a DNA-RNA duplex, inhibiting protein translation and modulating gene expression.
  • Advances in chemical synthesis and molecular biology have enhanced ASO stability, selectivity, and specificity.

Purpose of the Study:

  • To review the diverse applications of antisense technology in various disease areas.
  • To present supporting evidence from in vitro and in vivo studies.
  • To discuss the clinical potential of antisense-based therapies.

Main Methods:

  • Literature review of antisense oligonucleotide applications.
  • Analysis of studies demonstrating in vitro and in vivo efficacy.

Related Experiment Videos

  • Discussion of chemical and molecular biology advancements in ASO development.

    • Main Results:

    • Antisense technology is a versatile tool for studying gene regulation.
    • ASOs show potential as therapeutic agents for oncology, virology, genetic, and inflammatory diseases.
    • Significant progress has been made in improving ASO characteristics for therapeutic use.

    Conclusions:

    • Antisense oligonucleotides represent a powerful strategy for targeted gene modulation.
    • The technology holds considerable promise for the development of novel therapeutics across multiple medical fields.
    • Further clinical investigation is warranted to fully realize the potential of antisense therapies.